it is well recognised that the chance of healing is higher after the creation of a stool diverting stoma.4 5 However, from these retrospective studies it is difficult to differentiate whether the more rapid healing under ostomy protection is the consequence of changes in rectal disease activity or the lack of stool contamination.
The objective of the prospective study reported here was to describe the clinical course of perianal fistulas in patients with Crohn's disease. We determined the time course of inactivation of perianal fistulas and associated abscesses, the probabilities of healing and recurrent fistula activity, and the risk of re-opening of closed fistulas. Faecal diversion, rectal disease, the type of fistula, and medical treatment were evaluated as prognostic indicators of healing and symptomatic recurrence of fistulas.
Methods

PATIENTS
From May 1989 to October 1992, 106 consecutive patients with perianal fistulas were seen in a specialised Crohn's disease clinic in the Department of Surgery at the University of Tubingen. Sixteen patients could not be considered for the study. Nine patients were lost to follow up after initial presentation and therapy. Three patients with a long history of perianal fistulas presented with complete anal incontinence after multiple operations: they underwent proctectomy early after first presentation. The remaining four patients were referred from other centres to receive a transanal advancement flap in order to close the fistulas. The remaining 90 patients (53 women and 37 men) were included in the study and were followed up for a median of 22 months (range 6-44 months) until December 1993. Six hundred and twenty one follow up examinations were documented (mean 6-9 per patient). The patients were also seen regularly in the Department of Medicine of our University hospital. The diagnosis of Crohn's disease (CD) was firmly established in all patients.
The median duration of CD at the time of inclusion in the study was 8 years (range 0-22 disease was 4.5 (4.8) years. Four of the 90 patients presented without a history of perianal disease. In two of these patients Crohn's disease had not been diagnosed before. Forty one (47%) patients had had previous surgery for intestinal disease, and 69 (77%) patients for perianal fistulas or abscesses.
THERAPY OF PERIANAL FISTULAS AND ABSCESSES
The treatment policy during the study period was observation for asymptomatic fistulas and drainage of symptomatic fistulas and associated abscesses. During the later period selected patients without rectal disease were offered operative fistula closure by means of a rectal advancement flap repair (n=20). The results after this therapy will be reported in a separate paper.6 Perianal abscesses were drained by incision (80 abscesses in 45 patients) and, in patients with deep pus collection (n=25), by insertion of a mushroom catheter until macroscopically visible purulent discharge had stopped.
Active fistulas with purulent discharge and communication with the anal canal were drained by seton (47 setons in 39 patients) for a mean duration of 5.3 weeks, until purulent discharge or local pain had disappeared.
In seven patients a stool diverting stoma had been performed before their first presentation at our clinic. In another seven patients a diverting stoma was performed for severe perianal disease early during the study period. Two other patients received a stool diverting stoma at first symptomatic recurrence.
THERAPY OF ACTIVE INTESTINAL DISEASE
All patients in the study were Ten patients experienced no further active perianal disease during the entire study period. In addition to the 71 patients who entered the study with active fistulas as described above, nine further patients with initially inactive disease developed active disease early during the study. Recurrence of fistula activity after inactivation was studied in these 80 patients.
Forty two had at least one recurrence of fistula activity, at a median time interval of 3.8 months after inactivation. The probability of symptomatic recurrence was 35% after six months, 48% after one year and 59% after two years. The crude data on symptomatic recurrence are given in Table II Intestinal disease activity (CDAI) and rectal activity at the time of first symptomatic recurrence (n=36) were compared with the data documented at the examination before recurrence. The mean (SD) time interval between these two examinations was 3.8 (3.6) months. Rectal disease activity and CDAI before and at the time of recurrence are given in Table III . Discussion By using a standardised treatment and follow up protocol we evaluated the clinical course of perianal fistula disease. Active fistulas and perianal sepsis (abscesses) could initially be controlled effectively in all our patients with simple drainage procedures. However, the symptomatic recurrence rate was high (59% within two years). Except in a few patients, intestinal or rectal disease activity was not increased when fistula activity recurred. At the last follow up visit, 46% of the patients had healed fistulas. The chance of spontaneous fistula healing was 50% after two years. However, healing was followed by fistula re-opening or by the development of a new fistula in a comparably high percentage of patients (44% at 18 months after healing). The anatomical type of fistula turned out to be an important prognostic factor influencing both symptomatic recurrence and fistula healing.
Subcutaneous fistulas had the highest chance of healing and the lowest recurrence rate. In contrast, blind ischiorectal fistula tracts without a demonstrable internal opening in the anal canal or the rectum were characterised by low healing and high recurrence rates. The frequent absence of an internal opening in ischiorectal fistulas has previously been identified as an adverse prognostic indicator.'0 Proximal stool diversion significantly improved the course of the perianal fistulas (lower recurrence rate, higher chance of healing). Rectal involvement of Crohn's disease but not the macroscopic grading of inflammation of the rectal mucosa negatively influenced the course of perianal fistulas. Since the number of liquid stools did not correlate with symptomatic fistula recurrence, the presence of stool per se in the rectum or the passage of stool through the anal canal seem to be local factors that influence fistula activity independently of mucosal inflammation.
Immunosuppressive treatment did not influence the clinical course of perianal fistulas in our patients. Only eight of our patients received azathioprine. A favourable influence of 6-mercaptopurine/azathioprine on perianal The only paper dealing with the long term perspective using lifetable analysis reported a relatively low proctectomy rate. 14 However, the frequency of rectal involvement in these patients is not given.
Proctectomy may be the ultimate therapeutical possibility in rectal or perianal disease. As mentioned above proctectomy rates vary widely in the published reports. The median follow up in our study is too short to estimate the long term proctectomy rate in our patients with perianal fistulas. Proctectomy was necessary in two of our patients -one with severe anal stenosis and the other with intractable high grade proctitis. However, this low number may not reflect the overall proctectomy rate in patients with distal Crohn's colitis or perianal disease, which is probably higher.2 [15] [16] [17] The indications for a more aggressive surgical approach to treat perianal fistulas is a major point of discussion. With various surgical procedures (fistulotomy, partial fistulotomy, drainage), high healing rates were achieved (up to 85%) in selected groups of patients.10 13 16 18-24 Some of these papers reported only operations on active fistulas,22 others only in patients where an aggressive surgical approach seemed advisable (low lying fistulas and absence of rectal disease as evidenced by rates of rectal involvement in the studied patients as low as 30%,23 as opposed to 61% rectal involvement in our patients). Furthermore, accurate rates of fistula recurrence are frequently not available mostly because of incomplete data on the length of follow up. Actuarial methods of calculating such end points as healing or recurrence have not been used so far.
We recently began to use excisional surgery with fistula closure (endorectal advancement flap repair) in selected patients with transsphincteric and anovaginal fistulas.6 The recurrence rate after flap repair was high, comparable to recurrence rates in the present study. Anovaginal fistulas seem to recur more frequently after local repair than other transsphincteric fistulas.18 26 Since uncontrolled faecal drainage from the vagina is both uncomfortable and embarrassing for the patient, however, local repair of these fistulas may be worthwhile in these cases.24
The results of our prospective follow up indicate that the prognosis of perianal fistulas in Crohn's disease with regard to healing and recurrence may be worse than reported in previous studies. However, active perianal fistulas and associated abscesses could be controlled effectively without aggressive local surgery endangering the anal sphincter. After initial therapy of active fistulas, only a minority of patients had symptoms related to the perianal disease. The proctectomy rate was low in our patients, but this fact may change with a longer follow up period. The clinical course was improved by faecal diversion protecting the rectum and anal canal from contamination.
Other risk factors like fistula type and rectal disease give information on prognosis and help planning treatment in these patients. Intestinal or rectal disease activity appeared to influence the activity of perianal disease in a small number of patients only. A special treatment policy to control perianal disease by treating intestinal disease activity is not warranted therefore unless rectal disease activity itself gives rise to symptoms such as increased stool frequency or tenesmus.
